Biophytis Presented Its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris
Biophytis Presented Its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris
PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 1, 2024 / Biophytis SA (Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, presented the roll-out and results of its phase 2/3 COVA study in the treatment of severe forms of Covid-19 at the 6th edition of the World Congress on Infectious Diseases, held from June 24 to 26, 2024 in Paris, France.
2024年7月1日，生物物理學SA（Euronext Growth Paris：ALBPS）在巴黎、法國和劍橋、馬薩諸塞州發表了其2/3 COVA研究的推出和結果，旨在治療嚴重的新型冠狀病毒肺炎，這是一家專門致力於開發老年病治療藥物的臨床生物技術公司，在2024年6月24日至26日法國巴黎舉辦的第六屆世界傳染病大會上。
Professor Valerie Pourcher MD, PhD, Chaiman of the Infectious Diseases department at Pitié Salpetriere, presented the COVAphase 2/3 clincial study results in a context where the number of Covid cases rises again. Dr. Claudia Ferreira MD, PhD, Medical Director at Biophytis, opened the conference with a keynote presentation on the risk of infectious diseases and further pandemic developments associated with the Paris Olympic games including an increase of +52 %in emergency room (ER) visits due to SARS-CoV-2 on the week of 10-17 June 2024 in France. She also chaired several roundtables.
皮提·薩爾佩特利爾醫院傳染病科主任，教授Valerie Pourcher MD, PhD，在COVID-19病例再次上升的背景下，介紹了COVA 2/3期臨床研究的結果。Biophytis的醫學主管，Claudia Ferreira MD, PhD博士，在大會上發表了主題演講，討論了傳染病的風險以及與巴黎奧運會相關的進一步流行病發展，包括2024年6月10-17日一週內因SARS-CoV-2而造成急診室(ER)就診量增加52%的情況。她還主持了幾個圓桌討論。
Valerie Pourcher detailed the results of the randomised, placebo-controlled Phase 2/3 COVA study and the efficacy of oral BIO101 (20-hydroxyecdysone) administered orally in adult patients hospitalised for severe forms of COVID-19.
Valerie Pourcher詳細介紹了隨機分組、安慰劑對照的2/3期COVA研究的結果，以及口服BIO101 (20-羥基蛻蠍激素)在因COVID-19住院治療的成年患者中的療效。
The results of this phase 2-3 study, evaluating BIO101 in the treatment of severe hospitalised COVID-19 patients, are positive and show, in addition to a very good safety profile, a statistically significant reduction in the relative risk of early respiratory failure or death of 43.8% and a 44.6% reduction in the death rate over 90 days.
該2-3期研究評估了BIO101在治療重症COVID-19住院患者的作用，結果積極，除了具有非常好的安全性外，相對於早期呼吸衰竭或死亡也出現了統計上顯著的降低，降低幅度爲43.8％，在90天內死亡率也減少了44.6％。
Stanislas Veillet, CEO of Biophytis, stated: "The Covid pandemic is far from over: according to the World Health Organization, 134,797 new cases of Covid-19 and 1,691 deaths have been reported worldwide in the last 28 days as of June 9 - a figure that is underestimated due to under-reporting. Our COVA program, which showed very positive resullts, positions BIO101 (20-hydroxyecdysone) as a leading drug candidate for severe forms of Covid-19, particularly in elderly patients with co-morbidities, that is independent of the SARS-COV2 strain."
Biophytis的CEO Stanislas Veillet表示:“COVID-19大流行遠未結束: 根據世界衛生組織的數據，截至6月9日，在過去的28天中，全球報告了134,797例新的COVID-19確診病例和1,691例死亡病例 - 由於低報告率的原因，這個數字被低估了。我們的COVA計劃顯示出非常積極的結果，使BIO101（20-羥基蛻蠍激素）成爲治療COVID-19重症患者的主導藥物候選，特別是針對發生併發症的老年患者，不受SARS-COV2菌株的影響。”
The poster presented at the Congress, which details the objectives, the design and the results of the study, can be viewed by clicking on this link.
大會上展示的海報詳細介紹了研究的目標、設計和結果，可以通過單擊文章獲得。link.
****
****
About BIOPHYTIS
關於Biophytis
Biophytis SA is a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular (sarcopenia, phase 3 ready and Duchenne muscular dystrophy), respiratory (Covid-19 phase 2-3 completed) and metabolic diseases (obesity, phase 2 to be started). The company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825). For more information, visit
Biophytis SA是一家專注於開發針對老年疾病的藥物候選品的臨床階段生物技術公司。 BIO101（20-羥基蛻皮激素）是我們主要的藥物候選品，是一種小分子化合物，正在開發肌肉疾病（骨肌萎縮，第3階段準備就緒和杜氏肌萎縮症），呼吸系統疾病（完成Covid-19第2-3階段）和代謝性疾病（肥胖症，第2階段將開始）。該公司總部位於法國巴黎和馬薩諸塞州劍橋。其普通股在歐洲增長公司（股票代碼：ALBPS-ISIN：FR0012816825）上市。有關更多信息，請訪問
Forward-looking statements
前瞻性聲明 本新聞稿中包括的關於未來表現和結果、預期、規劃、策略、重點、承諾和其他聲明（包括與我們社會、環境和其他可持續性目標有關的聲明）的非歷史事實的前瞻性聲明，是根據美國聯邦證券法的定義而作出的前瞻性聲明。本新聞稿中關於我們環境和其他可持續性計劃和目標的前瞻性聲明以及其他聲明並不意味着這些聲明對於投資者、我們的業務、運營結果、財務狀況、前景或策略、對我們在可持續發展事項上的影響或其他當事方來說均是重要的，或者必須披露在我們向證券交易委員會（“SEC”）或其他監管機構的備案中。此外，歷史、現有及未來涉及社會、環境和可持續性的相關聲明可能是基於仍在發展的衡量進展的標準、不斷演變的內部控制和流程以及假設，在將來可能會發生變化。前瞻性聲明基於當前的信仰、期望和假設，並受到可能導致實際結果與前瞻性聲明有實質性差異的重大風險、不確定性和情況變化的影響。
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face» section from the Company's 2023 Financial Report available on BIOPHYTIS website () and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.
本新聞稿包含前瞻性聲明。前瞻性聲明包括所有非歷史事實陳述。 在某些情況下，您可以通過使用“前景展望”，“相信”，“期望”，“潛力”，“繼續，”，“可能”，“將” ，“應該”，“可能”，“尋求”，“預測”，“打算”，“趨勢”，“計劃”，“估計”，“預計” 或這些詞的負面版本或其他可比較的詞語來識別這些前瞻性陳述。 這類前瞻性聲明是基於Biophytis認爲合理的假設。然而，不能保證這些前瞻性陳述中包含的陳述將得到證實，這些陳述還可能受到各種風險和不確定性的影響。此 新聞稿中包含的前瞻性聲明也可能受到 Biophytis 尚未了解或目前不認爲重要的風險的影響。因此，存在或將存在重要因素可能導致實際結果或成果與這些聲明中指示的結果存在重大差異。此外，請參閱 Biophytis 網站上可用的2023年財務報告中的“公司即將面臨的風險與不確定性”部分以及20-F表格中的“風險因素”部分以及提交給美國證券交易委員會（SEC）的其他表格。我們沒有義務公開更新或審查任何前瞻性聲明，無論是因爲新的信息，未來的發展還是其他情況，除非法律要求。
Biophytis contacts
Biophytis聯繫方式
Investor relations
Nicolas Fellmann, CFO
Investors@biophytis.com
投資者關係
Nicolas Fellmann，CFO
Investors@biophytis.com
Media
媒體
Antoine Denry:antoine.denry@taddeo.fr- +33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr - +33 6 38 31 90 50
Antoine Denry：antoine.denry@taddeo.fr- +33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr - +33 6 38 31 90 50
SOURCE: Biophytis
來源：Biophytis
譯文內容由第三人軟體翻譯。